Arvinas (ARVN) Non-Current Assets (2017 - 2026)
Arvinas (ARVN) posted quarterly Non-Current Assets of $16.8 million for Q1 2026, down 21.5% year-over-year from $21.4 million in Q1 2025, and down 2.33% quarter-over-quarter from $17.2 million in Q4 2025.
Arvinas (ARVN) Non-Current Assets (2017 - 2026) Analysis & Trends
Arvinas' Non-Current Assets history runs 10 years deep, the most recent figure standing at $16.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 21.5% year-over-year to $16.8 million; the TTM figure through Mar 2026 stood at $71.8 million (down 16.51% YoY), while the FY2025 annual figure was $17.2 million, down 28.63% from the prior year.
- Non-Current Assets for Q1 2026 stood at $16.8 million, down from $17.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $31.3 million in Q1 2022, with the low at $16.8 million in Q1 2026.
- The 5-year median for Non-Current Assets is $24.1 million (2024), against an average of $23.8 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 87.81% in 2022, then sank 30.43% in 2024.
- Arvinas' Non-Current Assets stood at $28.6 million in 2022, then declined by 14.69% to $24.4 million in 2023, then slipped by 1.23% to $24.1 million in 2024, then fell by 28.63% to $17.2 million in 2025, then slipped by 2.33% to $16.8 million in 2026.
- Business Quant data shows ARVN's Non-Current Assets at $16.8 million in Q1 2026, $17.2 million in Q4 2025, and $18.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 22.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.90 Mn |
| Mar 31, 2026 | 16.80 Mn |
| Dec 31, 2025 | 17.20 Mn |
| Sep 30, 2025 | 18.00 Mn |
| Jun 30, 2025 | 19.80 Mn |
| Mar 31, 2025 | 21.40 Mn |
| Dec 31, 2024 | 24.10 Mn |
| Sep 30, 2024 | 17.60 Mn |
| Jun 30, 2024 | 22.90 Mn |
| Mar 31, 2024 | 22.30 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Sep 30, 2023 | 25.30 Mn |
| Jun 30, 2023 | 26.80 Mn |
| Mar 31, 2023 | 27.60 Mn |
| Dec 31, 2022 | 28.60 Mn |
| Sep 30, 2022 | 30.10 Mn |
| Jun 30, 2022 | 30.60 Mn |
| Mar 31, 2022 | 31.30 Mn |
| Dec 31, 2021 | 29.10 Mn |
| Sep 30, 2021 | 28.71 Mn |